vTv Therapeutics Inc. (VTVT) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 7 Buy, 7 Hold.
The consensus price target is $51.33 (low: $47.00, high: $58.00), representing an upside of 36.1% from the current price $37.72.
Analysts estimate Earnings Per Share (EPS) of $-3.65 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.20 vs est $-3.65 (beat +12.3%). 2025: actual $-3.20 vs est $-4.15 (beat +22.8%). Analyst accuracy: 78%.
VTVT Stock — 12-Month Price Forecast
$51.33
▲ +36.08% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for vTv Therapeutics Inc., the average price target is $51.33, with a high forecast of $58.00, and a low forecast of $47.00.
The average price target represents a +36.08% change from the last price of $37.72.
Highest Price Target
$58.00
Average Price Target
$51.33
Lowest Price Target
$47.00
VTVT Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to vTv Therapeutics Inc. in the past 3 months
EPS Estimates — VTVT
78%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$3.20
vs Est –$3.65
▲ 14.1% off
2025
Actual –$3.20
vs Est –$4.15
▲ 29.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VTVT
98%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▲ 1.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
